---
title: Corneal Epithelial Autograft for LSCD
nct_id: NCT03217487
overall_status: UNKNOWN
phase: NA
sponsor: Chunxiao Wang
study_type: INTERVENTIONAL
primary_condition: Limbal Stem Cell Deficiency
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03217487.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03217487"
ct_last_update_post_date: 2019-08-09
last_seen_at: "2026-05-12T06:38:38.384Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Corneal Epithelial Autograft for LSCD

**Official Title:** A Randomized Controlled Clinical Trial of Corneal Epithelial Autograft for the Treatment of Limbal Stem Cell Deficiency

**NCT ID:** [NCT03217487](https://clinicaltrials.gov/study/NCT03217487)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Chunxiao Wang
- **Conditions:** Limbal Stem Cell Deficiency
- **Start Date:** 2017-07-25
- **Completion Date:** 2019-12-30
- **CT.gov Last Update:** 2019-08-09

## Brief Summary

The purpose of the study is to explore whether femtosecond laser-assisted corneal epithelial autograft is more effective than limbal conjunctival autograft for ocular surface reconstruction in patients with limbal stem cell deficiency (LSCD).

## Eligibility

- **Minimum age:** 14 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Unilateral LSCD secondary to ocular burns, with the duration of disease of at least 24 months at the time of screening visit;
2. Presence of superficial neo-vascularization affecting at least 2 cornea quadrants and involving central cornea;
3. Informed consent signed by patient or legal guardian. Having the ability to comply with study assessments for the full duration of the study.

Exclusion Criteria:

1. LSCD of mild degree, with less than 2 quadrants of neo-vessel invasion and without central cornea involvement;
2. LSCD by ocular surface disorders other than pterygium;
3. Eyelids malposition;
4. The center corneal thickness\<450µm, the depth of corneal opacity \> 150µm;
5. High myopia with a spherical equivalent of -15.0 D or less;
6. Corneal or ocular surface infection within 30 days prior to study entry;
7. Ocular surface malignancy;
8. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;
9. Renal failure with creatinine clearance\< 25ml/min;
10. Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L;
11. Platelet levels \< 150,000 or \> 450,000 per microliter;
12. Hemoglobin \< 12.0 g/dL (male) or \< 11.0 g/dL (female);
13. Prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy;
14. Pregnancy (positive test) or lactation;
15. Participation in another simultaneous medical investigation or clinical trial;
16. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening;
17. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases;
18. Severe dry eye disease as determined by Schirmer's test \< 2mm at least in one eye;
19. Any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent;
20. Signs of current infection, including fever and treatment with antibiotics;
21. Active immunological diseases;
22. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.
```

## Arms

- **Corneal epithelial autograft** (EXPERIMENTAL) — Femtosecond laser assisted corneal epithelial autograft from the other eye in the treatment of LSCD
- **Limbal conjunctival autograft** (ACTIVE_COMPARATOR) — Diamond knife assisted limbal conjunctival autograft from the other eye in the treatment of LSCD

## Interventions

- **Corneal epithelial autograft** (PROCEDURE) — Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.
- **Limbal conjunctival autograft** (PROCEDURE) — A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.
- **Femtosecond laser** (DEVICE) — A commercial femtosecond laser to create a particular shaped graft for transplantation
- **Diamond knife** (DEVICE) — A diamond knife to create a particular shaped limbal graft for transplantation

## Primary Outcomes

- **Restoration of corneal surface in the diseased eye** _(time frame: 1 year)_ — Restoration of a completely epithelized, stable, and avascular corneal surface in the diseased eye.
- **Restoration of corneal surface in the fellow eye** _(time frame: 1 year)_ — Restoration of a completely epithelized, stable, and avascular corneal surface in the fellow eye.

## Secondary Outcomes

- **Uncorrected and best-corrected visual acuity in both eyes** _(time frame: 1 year)_
- **Corneal power, astigmatism and aberration in both eyes** _(time frame: 1 year)_
- **Corneal sensation in both eyes** _(time frame: 1 year)_
- **Corneal thickness in both eyes** _(time frame: 1 year)_
- **Density of stromal nerve and stromal keratocytes in both eyes** _(time frame: 1 year)_
- **Reconstruction of limbal palisades of Vogt in the diseased eye** _(time frame: 1 year)_
- **Corneal haze in both eyes** _(time frame: 1 year)_

## Locations (1)

- Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity, Guanzhou, Guangdong, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `locations.zhongshan ophthalmic center, sun yat-sen univerisity|guanzhou|guangdong|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03217487.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03217487*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*